Clinical Trial Results

Cathflo® Activase® (alteplase) is integral to evidence-based practices for treating thrombotically occluded catheters

Cathflo efficacy and safety were demonstrated in adult and pediatric patients with improperly functioning central venous access devices (CVADs) 2,8,10

The Cathflo clinical trials were large trials with prespecified endpoints in children and adults. In the pivotal trials COOL-1 and COOL-2, the efficacy and safety of Cathflo were evaluated in 1122 primarily adult patients, while CAPS evaluated 310 pediatric patients ages ranging from 2 weeks to 17 years. 2,8,10




CAPS=Cathflo Activase Pediatric Study; COOL=Cardiovascular Thrombolytic to Open Occluded Lines.

View COOL-1 publication

View COOL-2 publication

View CAPS publication

NEXT: Learn about the role of central venous access devices (CVADs) >

Bottle icon

The Association for Vascular Access (AVA) states that knowledge and understanding of current evidenced-based care and maintenance of best practices optimize outcomes and minimize complications. 6